乙肝表面抗原阳性慢性肝病（HBsAg+ve CLD）中的抗病毒治疗：究竟有多少患者真正需要它？
Antiviral therapy in HBsAg-positive chronic liver disease (HBsAg+ve CLD): how many patients really need it?
作者信息
Ascione A, Amitrano L, Riccio E, De Lella A, Canestrini C, de Bellis G, D'Alessandro R, Fiore R, Padulano P
出版信息
Hepatogastroenterology. 1984 Jun;31(3):123-4.
PMID:6469200
Abstract
One hundred and seventy-one consecutive patients with HBsAg+ve CLD were investigated in order to assess whether they were actively replicating the hepatitis B virus, and therefore eligible for antiviral therapy. Our results show that only 5.8% of patients were actively replicating B virus and therefore antiviral therapy, when available, could be used only for a small subgroup of patients suffering from CLD due to hepatitis B virus chronic infection.
摘要
对171例连续的HBsAg阳性慢性肝病患者进行了调查，以评估他们是否正在积极复制乙肝病毒，从而确定他们是否符合抗病毒治疗的条件。我们的结果显示，只有5.8%的患者正在积极复制乙肝病毒，因此，在有抗病毒治疗可用时，仅可用于一小部分因乙肝病毒慢性感染而患慢性肝病的患者。
Zotero 插件